Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Sales reached JPY86.4bn (+5.6% YoY), operating loss was JPY236mn, recurring profit was JPY85mn, net loss was JPY140mn.</li><li>Sales were JPY76.6bn (+6.0% YoY), operating profit was JPY1.7bn (-40.5% YoY), 7 new pharmacies opened, 2 closed.</li><li>Sales were JPY9.9bn (-5.6% YoY), operating loss was JPY461mn, 492 products offered, 47.6% in-house manufactured products.</li></ul>

Sales reached JPY86.4bn (+5.6% YoY), operating loss was JPY236mn, recurring profit was JPY85mn, net loss was JPY140mn.Sales were JPY76.6bn (+6.0% YoY), operating profit was JPY1.7bn (-40.5% YoY), 7 new pharmacies opened, 2 closed.Sales were JPY9.9bn (-5.6% YoY), operating loss was JPY461mn, 492 products offered, 47.6% in-house manufactured products.

日本調剤 (3341 JP)：2025年3月期第1四半期速報

Nihon Chouzai

日本調剤 (3341 JP)：2025年3月期第1四半期速報